All In Biotech

Drug Trial Radar · NCT03954483

Measurement of the Hippocampal Theta Rhythm From the Outer Ear Canal

Last checked: Nov 20, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Oct 16, 2023

Primary completion

Oct 1, 2026

Study completion Oct 1, 2027

Sponsor

Lead sponsor
University of ManitobaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 17, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

New technologies are needed to help diagnose anxiety disorders. EVestG has facilitated the identification of numerous possible biomarkers of several psychiatric disorders. Some EVestG features seem to be caused by differences in low-frequency modulation that is consistent (both in frequency and behaviour) with the hippocampal rhythm (theta), which is known to play a role in anxiety. Critically, there is ample support in the literature for an anatomical and functional basis for the modulation of vestibular signals via theta. If anxiety could be measured continuously, perhaps throughout a patient's day, or throughout a task, it might be able to confirm an anxiety disorder. However, current techniques for measuring theta are highly invasive, performed rarely, and only in epilepsy patients. EVestG technology, however, is non-invasive, and could potentially record anxiety levels in any subject for extended periods of time. The proposed study will attempt to identify hippocampal theta in vestibular signals in healthy participants through a double-blind administration of two different drugs that are dissimilar both pharmacologically and in acute clinical effects but which are known to reduce the theta rhythm.

Conditions

  • Anxiety

Interventions

  • Buspirone 10 Mg Oral TabletDrug

    Orally administered prior to experiments.

  • Triazolam 0.25 MG Oral TabletDrug

    Orally administered prior to experiments.

  • Placebo oral tabletDrug

    Orally administered prior to experiments.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EEG power spectrumTime frame: Derived from EEGs recorded for 30-45 mins
  2. 4-12 Hz modulationTime frame: Derived from EEGs recorded for 30-45 mins.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Riverview Health Centre

    Winnipeg, Manitoba, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.